 PCSK9 inhibitor drugs are now approved by the FDA to treat familial hypercholesterolemia.Drugs can inhibit PCSK9, leading to lowered circulating LDL particle concentrations.Since LDL particle concentrations are thought by many experts to be a driver of cardiovascular disease like heart attacks, it is plausible that these drugs may also reduce the risk of such diseases.